



NeuroScientific
BIOPHARMACEUTICALS

Level 1, 45 Stirling Highway
Nedlands WA 6009 Australia
www.neuroscientific.com

GLAUCOMA STUDY UPDATE

Perth, Australia; 24 December 2019: Drug development company NeuroScientific Biopharmaceuticals Ltd (ASX:NSB, “NSB” or the “Company”) has recently been advised that the results from its glaucoma animal study are expected to report in mid-to-late January 2020.

This pivotal preclinical study, involving NSB’s lead drug candidate EmtinB, is being run by researchers at the Lions Eye Institute and involves a pig model of raised intra-ocular pressure induced glaucoma. Success in this study will allow the Company to progress into testing EmtinB in glaucoma patients in clinical trials next year. Glaucoma is one of the leading causes of blindness in the world and EmtinB has the potential to be a leading disease modifying treatment for this disease.

On behalf of the Board of Directors of the Company, Brian Leedman (Non-executive Chairman) and Matt Liddelow (CEO and Managing Director) would like to wish all shareholders and supporters season’s greetings and a successful New Year.

About NeuroScientific Biopharmaceuticals Ltd

NSB (ASX:NSB) is a drug development company focused on developing peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need. The Company’s product portfolio includes EmtinB, a novel therapeutic peptide most advanced as a treatment for Alzheimer’s disease; and other related peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit www.neuroscientific.com

Contacts

Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+61 8 6382 1805

Brian Leedman
Non-executive Chairman
bl@neuroscientific.com
+61 412 281 780